Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003551 · ClinicalTrials.gov registry record · Phase 2
Aminocamptothecin in Treating Patients With Advanced or Recurrent Kidney Cancer
A Phase 2 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00003551: Completed Phase 2 study, sponsored by Emory University.
NCT00003551 is a Phase 2 study that has completed, run by Emory University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003551, a Phase 2 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients with stage III, stage IV, or recurrent kidney cancer.
Interventions
- DRUG aminocamptothecin colloidal dispersion
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-08 |
| Est. Completion | 2004-09 |
| Phase | Phase 2 |
What the finished NCT00003551 record still lists
NCT00003551 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which aminocamptothecin colloidal dispersion is the first listed.
NCT00003551 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003551 about?
NCT00003551 is a clinical study titled "Aminocamptothecin in Treating Patients With Advanced or Recurrent Kidney Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients with stage III, stage IV, or recurrent kidney cancer.
What is the current status of trial NCT00003551?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-08. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00003551?
The interventions under investigation include: aminocamptothecin colloidal dispersion (DRUG).
Who is sponsoring clinical trial NCT00003551?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia